Inclusion Criteria:

- Age > 18 years 2. All subjects must be female 3. Signed informed consent 4. >/- 10%
risk of carrying a BRCA-1 or BRCA-2 mutation. Risk will be estimated using the
probability models developed by Parmigiana, Couch, Myriad I, or Myriad II. The latter
three models require an affected proband; therefore, either the subject or a close
relative (the closest, youngest affected relative) can be used as the proband for the
purposes of calculating risk. If a relative is used as a substitute proband, the
subject's risk is estimated as the model risk for the relative, divided by 2 raised
to the power of the degree of relatedness. For example, suppose the subject's mother,
a first-degree relative, is her closest, youngest affected relative, and the Couch
estimate of risk for the mother is 16.2%. The subject's risk will be half of her
mother's [16.1/(2(1)) = 8.1%] and she would not be eligible. The risk for the subject
must be >/- 10%. Known mutation carriers are eligible regardless of their calculated
probability. A copy of a laboratory report stating results for known carriers must be
available for review as a source document. 5. If subjects are of reproductive
potential, they must be using a reliable contraceptive method or be sexually
abstinent. Reliable methods include tubal ligation, IUD, oral contraceptives, the
combination of spermicide and condom, or cervical cap and spermicide. Subjects must
fulfill these conditions beginning one month before beginning study medications and
ending one month after study termination. 6. Negative serum pregnancy test (bHCG)
done within one month of Day 1 and on Day 1 before study medication is taken. 7.
Adequate renal function, defined by serum creatinine within 1.5 times the
institution's upper limit of normal. 8. Adequate liver function, defined by total
bilirubin, SGOT, alkaline phosphatase and albumin, within 1.5 times the institutions
upper limits of normal. 9. Adequate bone marrow function, defined as a WBC > 4.0, a
platelet count > 100,000 and a hematocrit of >30. 10. Normal triglycerides for the
institution. 11. Normal TSH, T4. Patients on thyroid hormone supplementation are
eligible. 12. Have at least one breast that has never been involved with cancer and
has not been irradiated. 13. Willing to undergo 2 duplicate needle biopsies of the
breast. 14. Willing to have genetic testing for BRCA-1 and BRCA-2 mutations for
research purposes. Results will only be disclosed upon request of the participant.

Exclusion Criteria:

- Exclusion criteria: 1. Pregnancy, lactation or unwillingness to use a reliable
contraceptive method in women of childbearing potential. 2. Abnormal triglycerides,
greater than the institutional upper limit of normal. 3. Severe underlying chronic
illness or disease, such as uncontrolled diabetes. 4. Invasive cancer within the last
1 year, defined from the date of first diagnosis. 5. Current alcohol use >3
drinks/day. 6. History of pancreatitis. 7. Oral Vitamin A supplements greater than
the recommended daily requirement (5,000IU), therapeutic oral or topical Vitamin A
derivatives such as Accutane in the past 3 months prior to Day 1. 8. Tamoxifen or
other SERM use in the past 3 months prior to Day 1. 9. Postmenopausal hormone therapy
use, including estrogens or progestins in the past 3 months prior to Day 1. 10.
Chemotherapy for a neoplasm in the past 1 year. 11. Currently participating in a
study of an investigational agent. 12. Unwillingness to have BRCA-1 and BRCA-2
genetic testing for research purposes. 13. Medications known to be associated with
pancreatic toxicity or to increase triglyceride levels. 14. Biliary tract disease.
15. Uncontrolled hyperlipidemia. 16. Non-toxic goiter or thyroid enlargement.